Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Markham, C.M. Spencer, B. Jarvis.
Irbesartan. An updated review of its use in cardiovascular disorders.
Drugs, 59 (2000), pp. 1187-1206
[2.]
L. Mazzolai, M. Burnier.
Comparative safety and tolerability of angiotensin II receptors antagonists.
Drug Safety, 21 (1999), pp. 23-33
[3.]
R. Hariraj, E. Stoner, S. Jader, D.M. Preston.
Prolonged cholestasis associated with irbersartan.
BMJ, 321 (2000), pp. 547
[4.]
R.J. Andrade, M.I. Lucena, M.C. Fernández, J.L. Vega, M. García-Cortés, M. Casado, et al.
Cholestatic hepatitis related to use of irbesartan: a case report and a literature review of angiotensin II antagonists- associated hepatotoxicity.
Eur J Gastroenterol Hepatol, 14 (2002), pp. 887-890
[5.]
F. Tabak, A. Mert, R. Ozaras, M. Biyikli, R. Ozturk, G. Ozbay, et al.
Losartan-induced hepatic injury.
J Clin Gastroenterol, 34 (2002), pp. 585-586
[6.]
G. Basile, D. Villari, S. Gangemi, T. Ferrara, M.G. Accetta, V. Nicita-Mauro.
Candesartan cilexetil-induced severe hepatotoxicity.
J Clin Gastroenterol, 36 (2003), pp. 273-275
[7.]
A. Kiykim, E. Altintas, O. Sezgin, K. Sezer, N. Tiftik, E. Akbay, et al.
Valsartan-induced hepatotoxicity in a HBsAg-positive patient.
Am J Gastroenterol, 98 (2003), pp. 507
[8.]
Report of an International Consensus Meeting.
Criteria of druginduced liver disorders.
J Hepatol, 11 (1990), pp. 272-276
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
